Targeted therapies have been moved forward in the treatment of both pemphigus and pemphigoid diseases, a factor behind an urgency for rapid diagnosis.

This is a rare autoimmune skin disorder that occurs when your immune system starts attacking healthy epidermis cells (the top layer of your skin). Pemphigus can manifest itself as blisters and sores ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Significantly ...

Please provide your email address to receive an email when new articles are posted on . Research shows nearly 20% of patients with pemphigus experience relapse. An additional dose of rituximab in ...

Rilzabrutinib, a novel oral reversible Bruton's tyrosine kinase inhibitor, delivered rapid control of pemphigus disease activity accompanied by markedly reduced need for systemic corticosteroids in ...

Susan Bard, MD, is a board-certified general and procedural dermatologist with the American Board of Dermatology and a Fellow of the American College of Mohs Surgery. Pemphigus is a rare autoimmune ...

Please provide your email address to receive an email when new articles are posted on . A trial of adjuvant immunoadsorption for pemphigus diseases was ended early due to adverse events. The time to ...

Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases.

Rituximab and mycophenolate mofetil are used to treat pemphigus vulgaris, but they have not been adequately compared in clinical trials. In a randomized, controlled trial, we assigned patients with ...